The FDA has released new guidance aimed at enhancing the development of stand-alone devices and combination products designed for drug and biological product delivery. This guidance emphasizes the importance of consistent drug delivery performance information in regulatory applications, which is critical for ensuring the efficacy and safety of these products.
This initiative comes in response to the growing complexity of drug delivery systems and the need for standardized performance metrics. By establishing clear expectations for the data required in submissions, the FDA seeks to streamline the review process, thereby accelerating the time to market for innovative therapies.
The implications for pharma B2B professionals are significant, as adherence to these guidelines will be essential for regulatory compliance. Companies involved in the development and manufacturing of drug delivery devices must now prioritize the generation of robust performance data to meet these new standards, ultimately impacting their product development timelines and market strategies.
Open the full market picture for your next decision →
